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ABSTRACT
We analyse variations in cost or length of stay (LoS) for 66 587 patients from 10 European countries receiving a coronary
artery bypass graft (CABG) procedure. In ﬁve of these countries, variations in cost are analysed using log-linear models. In
the other ﬁve countries, negative binomial regression models are used to explore variations in LoS. We compare how well
each country’s diagnosis-related group (DRG) system and a set of patient-level characteristics explain these variations. The
most important explanatory factors are the total number of diagnoses and procedures, although no clear effects are evident
for our CABG-speciﬁc diagnostic and procedural variables. Wound infections signiﬁcantly increase LoS and costs in most
countries. There is no evidence that countries using larger numbers of DRGs to group CABG patients are better at
explaining variations in cost or LoS. However, reﬁnements to the construction of DRGs to group CABG patients might
recognise ﬁrst and subsequent CABGs or other speciﬁc surgical procedures, such as multiple valve repair. Copyright ©
2012 John Wiley & Sons, Ltd.
KEY WORDS: diagnosis-related groups; cost analyses; length of stay; CABG
1. INTRODUCTION
Diagnosis-related group (DRG) systems are designed to classify patients into resource homogenous groups that
describe the type of patients treated in hospitals (Fetter, 1991; Kobel et al., 2011). Although patients allocated
to the same DRG should have the same expected resource requirements, their actual resource use will vary. If
variation is not random, the use of DRGs to compare or reimburse hospitals is undermined. This makes it
important to evaluate how well DRGs explain variation in resource use. In this article, we focus on DRGs used
to classify patients having coronary artery bypass graft (CABG) surgery, a revascularisation operation that
diverts blood ﬂow around an occluded (blocked or restricted) coronary vessel.
There are two prime facie reasons to suspect that DRGs describing patients having CABG can be improved.
First, DRGs may have failed to keep pace with the rate of technological change in this area, which, in turn, has
led to changes in the proﬁle of patients having treatment (McClellan and Kessler, 2002; National Institute for
Health and Clinical Excellence, 2011; Yock et al., 2000; Zenalti et al., 1997). Alternatives to bypass
procedures have been developed, such as percutaneous transluminal coronary angioplasty (PTCA), where
the occluded vessel is widened, and usually, a stent is implanted. These generally delay, rather than obviate,
the need for a bypass, which, as a result, is increasingly being performed on older and sicker patients (Cutler
and Huckman, 2003; Goldman et al., 2006; Natarajan et al., 2007). Second, most countries have developed
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their own DRG systems, and there is large variation both in the number of DRGs used to describe CABG
patients, and in how these DRGs are structured (Table I). This raises the possibility that some DRG systems
are better than others at classifying patients into resource homogenous groups.
In what follows, we examine the ability of: (i) different European DRG systems and (ii) various patient-
level characteristics to explain variations in cost or length of stay (LoS), for patients undergoing CABG.
We do this by analysing patients from each of 10 countries separately. We evaluate the relative
explanatory power of these two sets of variables and assess whether there is scope to improve existing
DRGs for these patients. We draw out common messages across countries with regard to what explains cost
or LoS and the relative performance of the different DRG systems.
2. METHODS
2.1. Data and variables
Patients from each of 10 countries are included if they are at least one year old and underwent a coronary artery
bypass graft (procedure code 36.1 in ICD-9-CM)1 during 2008. The exceptions are England and Poland where
2007/08 and 2009 data are used. In Austria, England, France, Ireland, Poland, Spain (Catalonia) and Sweden, the
data cover all cases; in Estonia, Finland and Germany, all patients from only a sample of hospitals is used. The
proportion of national cases covered by each country’s data, ranging from 3% in Germany to 100% in England, is
shown in Table II. For ﬁve countries (England, Estonia, Finland, Germany and Sweden), variations in cost are
analysed using ﬁxed-effects log-linear models, whereas for the other ﬁve (Austria, France, Ireland, Poland and
Spain), LoS is evaluated using negative binomial regression models. An overview of data sources, analytical
methods and core variables is provided elsewhere in this issue (Street et al., 2012).
Additional CABG-speciﬁc variables distinguish between patients with unstable angina (I20.0 in ICD-10),
acute myocardial infarction (AMI; I21-I22 in ICD-10),2 atrial ﬁbrillation (I48 in ICD-10) and acute renal failure
(ARF; N17 in ICD-10) (Austin et al., 2002; Austin et al., 2003; Speir et al., 2009). Procedural variables
account for patients who, in the same hospital stay where they received a CABG operation, also underwent
a PTCA (36.01, 36.02 or 36.05 in ICD-9-CM) or valve repair or replacement (35.0-2 in ICD-9-CM). We also
identify any case with more than one bypassed vessel (multivessel CABG). Finally, we include a dummy var-
iable to capture all cases where more than one CABG procedure was performed (multiple CABG), which
includes cases of reoperation (during the same hospital stay) and cases where more than one vein harvesting
site was used.
We estimate three explanatory models: the ﬁrst model (MD) includes only the country’s DRGs to which
CABG patients are grouped; the second model (MP) uses a set of patient-level characteristics and CABG-speciﬁc
variables that can be constructed from routine data; and the third model (MF) includes both sets of explanators.
In each model, our dependent variable is either log of cost or LoS. All three models also account for clustering
of patients within hospitals, either via a ﬁxed effect (cost) or via hospital dummies (LoS) (Street et al., 2012).
2.2. Diagnosis-related group structure
Diagnosis-related groups that cover patients undergoing bypass operations are deﬁned primarily by the treatment
used. However, the number and type of distinctions that DRG systems use to classify CABG patients varies widely
across countries, as summarised in Table I. At the extremes, the Polish system uses two DRGs, while the French
system uses 15 DRGs.
1Outpatients were excluded.
2As a result AMI is omitted when we construct our Charlson Index of comorbidities for CABG. Instead, it appears as a condition-speciﬁc
variable.
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There is considerable variation in the characteristics used to deﬁne DRGs. In seven of the 10 countries, separate
DRGs are included for the use of catheterisation in addition to a bypass procedure. There is generally also an
adjustment for concurrent valve procedures. Six systems take account of patient comorbidities or complications
(CC), but the approach varies, from a simple dichotomy (with/out CCs) in Poland, to four levels of CCs and
interactions with catheterisation and death in France. The Irish system classiﬁes cases with ‘catastrophic’ and/or
‘severe’ CCs, and the Spanish system also focuses on major CCs, whereas in Austria, Germany, England and
Estonia no CC adjustment is made.
3. RESULTS
3.1. Descriptive statistics
As reported in Table II, the number of patients available for analysis ranges from 204 (Estonia) to 19 522
(England), treated in between one (Finland) and 58 (France) hospitals. The mean LoS across countries ranges
from 9 (Finland and Sweden) to 17 days (Ireland and Spain). Most CABG patients are male (range: 68% (Estonia)
to 82% (Ireland)), and mean age is around 67 years, with little variation in the average across countries.
The majority of CABG cases are electives, with France and Finland undertaking less than 5% as emergencies.
However, the proportion of emergencies is over 35% in Ireland and Poland. The rate of transfers into hospital
from other providers ranges from 8% in Finland to 41% in Sweden. In Estonia, 3% of patients are discharged
to other providers, compared with 79% in France. The in-hospital mortality rate varies from 1% (Sweden) to
almost 7% (Germany).
The rates of recorded non-severe co-morbidity (Charlson index = 1) ranges from 4% (Finland) to 59%
(Estonia) and the range for major comorbidities (Charlson index = 2) from just over 1% (Finland) to 57%
(Germany). Finland has the lowest rate of recorded atrial ﬁbrillation (under 3%) and, like Estonia, no reported
cases of acute renal failure. The highest rate of atrial ﬁbrillation is in Germany (32%), whereas Spain has the
highest rate of acute renal failure (8%). The rate of unstable angina ranges from less than 2% (Estonia) to
42% (Sweden), and of AMI from 1% (Finland) to 38% (Germany). The mean number of total diagnoses ranges
from less than 2 (Finland) to almost 12 (Germany).3
There is also wide variation in the types of procedures performed, which may be due to differences in
clinical circumstances, hospital policies or to differential practice across countries in what patient information
is captured in the electronic record. The proportion of patients having multiple CABGs in the same hospital stay
3The low rates in Finland are largely because of the limited coding of secondary diagnoses.
Table I. Overview of the DRGs used to classify CABG patients in 10 European countries
Diagnosis-related group split variables
Country (system) Number of DRGs
Complication/
comorbidity Catheterisation
Valve
procedure Other adjustments
Austria (LKF) 5 --- --- x Age
England (HRG) 4 --- x x First CABG
Estonia (NordDRG) 3 --- x x ---
Finland (NordDRG) 6 x x x ---
France (GHM) 15 x x x LoS, death
Germany (G-DRG) 13 --- x x Age
Ireland (AR-DRG) 8 x --- x ---
Poland (JGP) 2 x --- --- Age
Spain (AP-DRG) 8 x x x ---
Sweden (NordDRG) 6 x x x ---
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Table II. CABG patients in 10 European countries: descriptive statistics
Country Austria France Ireland Poland Spain
LoS LoS LoS LoS LoS
No. of patients 4152 19444 1039 13029 1169
% national cases (approx)* 98% 97% 99% 90% 14%
No. of hospitals 9 58 4 26 7
Dependent variable Mean (SD)
Cost € NA (NA) NA (NA) NA (NA) NA (NA) NA (NA)
Logarithm of cost NA (NA) NA (NA) NA (NA) NA (NA) NA (NA)
Length of stay 15.99 (9.11) 13.82 (7.67) 16.78 (12.96) 10.80 (5.58) 17.39 (13.47)
Variables, patientb Percentage of patients (%)
DRG1 3.66 21.59 22.43 35.40 34.05
DRG2 69.32 7.17 3.56 64.13 10.86
DRG3 20.04 24.19 7.60 12.23
DRG4 1.37 3.54 44.75 3.25
DRG5 3.40 7.58 5.39 24.12
DRG6 1.12 7.99 1.11
DRG7 9.12 2.69 9.67
DRG8 7.63 4.62 3.17
DRG9 2.26
DRG10 4.54
DRG11 3.14
DRG12 1.36
DRG13 2.31
DRG14 1.10
DRG15 1.47
Other DRGs 2.22 1.88 0.96 0.48 1.54
Male 75.12 79.93 82.29 73.90 80.41
Transfer in 14.57 16.47 29.16 NA 20.10
Transfer out 29.99 79.01 21.08 41.91 12.75
Emergency 25.48 2.93 36.86 37.48 25.06
Deceased 3.59 4.25 3.37 2.20 5.73
Charlson index = 1 27.60 34.04 27.53 29.70 36.44
Charlson index = 2 20.50 30.36 18.19 8.61 24.55
Unstable angina 6.36 18.99 16.36 26.72 11.80
Atrial ﬁbrillation 11.18 25.74 26.76 9.17 22.93
AMI 15.00 20.66 20.50 3.65 33.96
ARF 1.83 6.75 5.20 0.20 7.96
Multiple CABG 22.95 0.92 NA NA 71.26
PTCA 1.71 1.64 NAa NA 1.71
Multivessel CABG 76.90 77.79 90.86 69.86 90.33
Valve surgery 22.74 21.04 13.09 0.91 23.18
Adverse event 1.18 4.27 3.85 0.05 4.11
Urinary tract infection 0.39 3.27 1.54 0.00 3.34
Wound infection 1.45 1.75 10.11 0.00 4.96
Mean (SD)
Age 67.65 (9.75) 67.70 (10.42) 65.74 (9.36) 64.40 (9.14) 66.44 (10.07)
No. of diagnoses 4.59 (2.96) 8.27 (4.76) 7.44 (3.53) 2.40 (1.12) 7.59 (2.30)
No. of procedures 3.84 (2.17) 13.84 (6.04) 9.23 (3.43) 6.28 (3.88) 5.27 (2.17)
Variables, hospital Percentage of hospitals (%)
Teaching hospital 33.33 50.00 100.00 57.69 100.00
Private hospital 0.00 46.55 0.00 NA 0.00
Mean (SD)
Hospital volume (in 1000s) 74.84 (17.14) 76.25 (64.29) 80.89 (18.75) 27.43 (16.22) 33.32 (14.53)
Share of CABGpatients (%) 0.675 (0.296) 0.968 (1.180) 0.345 (0.179) 6.145 (13.187) 0.504 (0.251)
Specialisation index 0.209 (0.044) 0.381 (0.234) 0.373 (0.047) NA (NA) 0.185 (0.104)
adv_event_1 2.23 (1.28) 15.60 (17.33) 11.28 (5.89) 5.00 (5.00) 0.38 (0.32)
adv_event_2 3.61 (1.53) 12.89 (7.71) 8.72 (4.25) 2.00 (1.00) 0.20 (0.18)
aData not reported to protect patient conﬁdentiality; *Based on OECD 2008 data and Hospital Episode Statistics (England only); numbers
are indicative; bDRG variables ordered by ascending DRG weights (DRGs vary by country). NA, Not available.
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Table II. (Continued)
Country England Estonia Finland Germany Sweden
Log cost Log cost Log cost Log cost Log cost
No. of patients 19522 204 646 3165 4217
% national cases (approx)* 100% N/A 21% 3% 92%
No. of hospitals 28 2 1 4 7
Dependent variable Mean (SD)
Cost € 13193 (4266) 8514 (4499) 16627 (9353) 12988 (7137) 18199 (9567)
Logarithm of cost 9.03 (0.37) 8.98 (0.33) 9.61 (0.42) 9.37 (0.44) 11.98 (0.41)
Length of stay 12.48 (10.94) 13.79 (11.72) 8.78 (4.05) 14.22 (8.90) 8.97 (4.21)
Variables, patientb Percentage of patients (%)
DRG1 85.18 25.00 46.28 43.16 32.23
DRG2 1.72 64.22 1.39 4.01 44.08
DRG3 1.18 8.33 2.63 10.33 1.52
DRG4 6.51 33.13 3.92 1.21
DRG5 3.41 2.94 2.28
DRG6 11.61 7.77 13.02
DRG7 4.64
DRG8 4.33
DRG9 1.99
DRG10 3.51
DRG11 1.17
DRG12 2.24
DRG13 1.14
Other DRGs 5.41 2.45 1.55 8.85 5.67
Male 78.73 68.14 73.53 75.89 78.21
Transfer in 25.34 17.16 8.05 27.74 40.55
Transfer out 7.33 3.43 28.17 74.60 77.57
Emergency 10.73 9.80 4.18 9.04 24.50
Deceased 2.55 1.96 2.01 6.64 1.09
Charlson index = 1 29.35 59.31 4.02 25.21 27.79
Charlson index = 2 16.78 28.92 1.39 56.62 7.61
Unstable angina 7.18 1.47 6.97 13.18 41.74
Atrial ﬁbrillation 23.04 14.71 2.63 32.16 24.52
AMI 7.79 2.45 1.08 37.57 20.11
ARF 1.39 0.00 0.00 2.84 0.88
Multiple CABG 80.36 0.00 72.91 72.01 80.70
PTCA 0.82 0.00 1.39 1.74 0.69
Multivessel CABG 66.29 0.00 62.38 72.58 68.44
Valve surgery 15.77 0.49 49.23 23.57 15.77
Adverse event 1.53 0.00 0.15 2.75 0.62
Urinary tract infection 1.27 0.00 0.00 4.58 0.83
Wound infection 2.81 0.49 0.00 2.75 1.00
Mean (SD)
Age 67.07 (9.76) 66.40 (8.70) 67.86 (9.60) 68.03 (9.33) 67.60 (9.22)
No. of diagnoses 6.60 (3.33) 3.80 (1.22) 1.41 (0.83) 11.55 (6.68) 3.94 (2.23)
No. of procedures 3.69 (2.31) 1.86 (0.43) 10.31 (2.33) 8.35 (4.66) 4.39 (2.11)
Variables, hospital Percentage of hospitals (%)
Teaching hospital 64.29 50.00 100.00 NA 100.00
Private hospital 0.00 0.00 0.00 25.00 0.00
Mean (SD)
Hospital volume (in 1000s) 122.48 (56.46) 40.79 (3.54) 344.61 (0) 18.62 (10.65) 58.74 (32.68)
Share of CABGpatients (%) 1.202 (2.159) 0.244 (0.149) 0.191 (0) 6.505 (6.275) 1.189 (0.573)
Specialisation index 0.240 (0.238) NA (NA) 0.154 (0) 0.679 (0.298) 0.096 (0.036)
adv_event_1 8.64 (5.04) 0.00 (0.00) 10.10 (0.00) 28.00 (10.70) 18.97 (3.95)
adv_event_2 11.72 (4.44) 0.00 (0.00) 14.50 (0.00) 15.31 (3.77) 13.87 (2.14)
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ranges from none in Estonia to 81% in Sweden. No one in Estonia is recorded as having a multivessel CABG,
whereas 91% of patients do so in Ireland. The ﬁgures for the use of a valve procedure range from under 1%
(Estonia) to 49% (Finland). Only the use of PTCA in the same stay as a CABG is consistently low at less than
2% for all countries. The lowest average number of procedures performed per patient is 2 (Estonia), whereas
the highest is 14 (France).
Ireland stands out with a rate of wound infection of 10%. Elsewhere, the rates of adverse events and
infections do not exceed 5%. It is important to bear in mind that these observed rates may reﬂect differences
in coding practice rather than real differences in incidence rates.
3.2. Regression results
3.2.1. Stage 1. Results for our three models explaining variation in patient costs or LoS are reported for
each country in Table III (Part I and Part II).4 The highest volume DRG forms the reference group, and the
DRGs are ranked in ascending order of their reimbursement rate. In the ﬁrst model (MD) that considers DRGs
without any other covariates, most DRGs are signiﬁcant (0.1% level), and the magnitude generally increases in
line with the price each national system attaches to them.
Our second model (MP) employs a set of patient-level characteristics as its regressors, including measures of
clinical practice and quality. Neither age nor gender inﬂuences cost, but age is a signiﬁcant predictor of LoS for
those aged over 70 in Poland and those over 75 in Austria and France, where men have a signiﬁcantly lower
LoS than women. Austin et al. (2003) found age and gender to have a similarly signiﬁcant impact on LoS.
In almost all countries, the variables assessing the total number of different diagnoses and total number of pro-
cedures have positive and signiﬁcant coefﬁcients for LoS and cost. Patients who are transferred into hospital have
signiﬁcantly longer LoS in France, whereas those transferred out have a shorter LoS in Austria, France and Poland.
In England, patients who are transferred between hospitals have signiﬁcantly higher costs than those who are
treated in a single institution, but Swedish patients who are transferred into hospitals have lower costs. Patients
admitted as emergencies have signiﬁcantly longer LoS in France, Poland and Spain and signiﬁcantly higher costs
in Germany and Sweden. In-hospital mortality is associated with signiﬁcantly shorter LoS (Austria, France and
Poland) and lower costs (Germany), suggesting that if death occurs, it happens soon after CABG surgery.
Patient complexity, as captured by Charlson co-morbidities, does not signiﬁcantly predict LoS or cost,
except in Sweden where the presence of severe comorbidity increases costs by 11%.5 Of the condition-speciﬁc
diagnoses, AMI is the most frequently signiﬁcant, associated with a lower LoS in Austria, lower costs in
England and higher costs in Sweden. In France, both ARF and atrial ﬁbrillation increase LoS (by around 6%
and 3%, respectively); ARF increases costs in Sweden by 87%. Unstable angina does not signiﬁcantly
inﬂuence resource use in any country.
Few of the procedure dummy variables help explain resource use. Costs are signiﬁcantly lower for Swedish and
Finnish patients who undergomultiple CABGs. Patients who have valve surgery have a signiﬁcantly longer LoS in
Poland and higher costs in England, Germany and Sweden. Multivessel CABG has no effect on LoS but signiﬁ-
cantly increases costs in Germany by 7%, and PTCA has no effect on costs or LoS, except in Sweden where PTCA
increases costs by around 26%.
Wound infections signiﬁcantly increase LoS and costs in all countries except Sweden and Poland. The indicators
of patient safety have less impact, although their occurrence increases LoS in France and costs in Finland.
We now compare the relative ability of DRGs and our set of patient-level characteristics to explain
variations in costs or LoS. In England, the explanatory power of models MD and MP are identical
(R2 = 0.49), a little lower than that achieved when both models are combined in MF (R
2 = 0.51). This suggests
that the four English DRGs are performing a similar function to our set of patient-level characteristics.
4Table III shows only the coefﬁcients without standard errors. The full table is available at http://www.eurodrg.eu.
5
Calculated as exp b^
 
 1 (Halvorsen and Palmquist, 1980).
J. GAUGHAN ET AL.82
Copyright © 2012 John Wiley & Sons, Ltd. Health Econ. 21(Suppl. 2): 77–88 (2012)
DOI: 10.1002/hec
T
ab
le
II
I.
R
es
ul
ts
fr
om
th
e
pa
tie
nt
-l
ev
el
re
gr
es
si
on
s
fo
r
C
A
B
G
:
co
st
an
al
ys
es
(P
ar
t
I)
D
ep
en
de
nt
va
ri
ab
le
:
lo
g
of
co
st
E
ng
la
nd
E
st
on
ia
F
in
la
nd
G
er
m
an
y
S
w
ed
en
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
D
R
G
1
re
f
re
f
0.
18
1*
*
0.
07
9
re
f
re
f
re
f
re
f
0
.2
19
**
*
0
.1
25
**
*
D
R
G
2
0.
15
9*
**
0.
08
9*
**
re
f
re
f
0.
21
3*
*
0.
09
6
0.
18
3*
**
0.
04
6*
re
f
re
f
D
R
G
3
0
.0
09
0
.0
46
0.
01
2
0
.0
31
0.
48
5*
**
0.
39
8*
**
0.
16
9*
**
0.
06
4*
*
0.
13
1*
*
0.
01
8
D
R
G
4
0.
11
8*
**
0.
05
9*
**
0.
43
2*
**
0.
15
9*
**
0.
24
6*
**
0.
07
0*
0.
09
7*
**
0.
01
4
D
R
G
5
0.
32
9*
*
0.
05
7
0.
34
8*
**
0.
12
2*
**
0.
23
3*
**
0.
20
5*
**
D
R
G
6
0.
56
3*
**
0.
25
9*
**
0.
28
7*
**
0.
20
5*
**
0.
36
1*
**
0.
16
2*
D
R
G
7
0.
30
8*
**
0.
12
0*
**
D
R
G
8
0.
46
3*
**
0.
25
2*
**
D
R
G
9
0.
53
6*
**
0.
12
3*
**
D
R
G
10
0.
69
8*
**
0.
32
3*
**
D
R
G
11
0.
84
1*
**
0.
39
3*
**
D
R
G
12
0.
99
3*
**
0.
47
5*
**
D
R
G
13
1.
26
7*
**
0.
55
6*
**
O
th
er
D
R
G
s
0
.2
07
**
*
0
.2
86
**
*
0.
95
3*
**
0.
80
9*
*
0.
92
9*
**
0.
57
5*
**
0.
75
8*
**
0.
35
3*
**
0.
21
8*
**
0.
12
7*
**
A
ge
:
1–
60
0
.0
02
0
.0
01
0.
01
2
0.
01
1
0.
01
9
0.
01
5
0
.0
02
0
.0
02
0.
01
0.
00
9
A
ge
:
60
–6
5
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
A
ge
:
66
–7
0
0
0.
00
1
0
.1
07
0
.1
02
0.
07
5
0.
05
1
0.
00
6
0.
00
8
0.
01
3
0.
01
5
A
ge
:
71
–7
5
0
.0
04
0
.0
03
0
.0
64
0
.0
56
0.
09
8*
0.
09
3*
*
0.
00
4
0.
00
6
0.
01
6
0.
01
7
A
ge
:
76
+
0
.0
01
0.
00
1
0.
05
2
0.
03
9
0.
12
3*
*
0.
09
5*
0.
01
1
0.
00
9
0.
03
1
0.
03
4*
M
al
e
0.
00
8
0.
00
8
0
.0
69
0
.0
41
0
.0
19
0
.0
15
0.
01
5
0.
00
9
0
.0
19
0
.0
22
D
ia
gn
os
es
0.
00
4*
**
0.
00
6*
**
0.
03
6
0.
02
3
0.
16
0*
**
0.
12
2*
**
0.
00
8*
**
0.
00
6*
**
0.
01
1*
0.
00
2
P
ro
ce
du
re
s
0.
01
6*
**
0.
02
0*
**
0
.0
47
0
.0
27
0.
09
2*
**
0.
07
9*
**
0.
06
7*
**
0.
05
0*
**
0.
05
5*
**
0.
05
0*
**
T
ra
ns
fe
r
in
0.
03
3*
**
0.
03
7*
**
0.
06
4
0.
05
0
.1
62
*
0
.1
5
0.
01
3
0.
01
3
0
.0
71
**
*
0
.0
76
**
*
T
ra
ns
fe
r
ou
t
0.
03
6*
**
0.
03
6*
**
0.
13
8
0.
22
8*
0.
04
8
0.
06
0
.0
21
0
.0
22
0.
04
3*
0.
05
0*
*
E
m
er
ge
nc
y
0
.0
21
*
0
.0
11
0.
07
7
0
.0
09
0.
08
0*
0.
06
5*
0.
06
0*
**
0.
05
6*
**
0.
13
1*
**
0.
13
5*
**
D
ec
ea
se
d
0
.0
43
*
0
.0
34
0
.1
18
0
.0
54
0.
11
7
0.
08
0
.2
57
**
*
0
.2
80
**
*
0.
19
7
0.
18
7
C
h_
in
de
x
=
1
0.
00
4
0.
00
3
0.
06
6
0.
08
0
.0
93
0
.0
72
0
.0
04
0.
00
2
0.
04
0*
*
0.
03
9*
*
C
h_
in
de
x
=
2
0.
01
8*
*
0.
01
8*
*
0.
17
5
0.
12
9
0
.1
45
0
.1
22
0
.0
14
0.
00
1
0.
10
2*
**
0.
09
4*
**
U
ns
ta
bl
e
an
gi
na
0
.0
26
*
0
.0
24
*
0
.0
19
0.
00
1
0.
05
2
0.
03
8
0
.0
04
0
.0
08
0.
03
4*
0.
04
0*
*
A
tri
al
ﬁ
br
ill
at
io
n
0.
00
9
0.
00
4
0.
08
3
0.
07
4
0
.1
23
0
.1
03
0.
01
4
0.
01
5
0.
03
0*
0
.0
17
A
M
I
0
.0
46
**
*
0
.0
41
**
*
0.
44
5*
*
0.
33
0.
00
4
0.
10
1
0
.0
2
0
.0
16
0.
06
5*
**
0.
01
8
A
R
F
0.
02
3
0.
03
2
0
0
0
0
0.
08
0.
04
2
0.
62
8*
**
0.
62
2*
**
M
ul
tip
le
C
A
B
G
s
0
.0
04
0
.0
12
0
0
0
.1
23
**
*
0
.0
53
0
.0
34
**
0
.0
09
0
.0
93
**
*
0
.0
73
**
*
P
T
C
A
0
.0
55
0
.0
53
0
0
0.
06
3
0.
09
7
0
.0
25
0
.0
08
0.
22
9*
**
0.
24
6*
**
M
ul
tiv
es
se
lC
A
B
G
0.
01
2*
*
0.
00
9*
0
0
0.
06
1*
0.
06
9*
*
0.
06
4*
**
0.
06
3*
**
0.
03
1*
*
0.
02
9*
V
al
ve
su
rg
er
y
0.
02
9*
**
0.
01
3
0.
05
3
0.
02
9
0.
02
8
0
.0
01
0.
09
2*
**
0
.0
39
0.
30
3*
**
0.
14
4*
A
dv
er
se
ev
en
t
0.
04
3*
0.
04
4*
0
0
0.
75
7*
**
0.
75
0*
**
0.
01
7
0.
01
3
0.
24
3*
*
0.
24
0*
*
U
T
I
0.
00
3
0.
00
1
0
0
0
0
0.
03
8
0.
03
3
0.
02
2
0.
03
5
W
ou
nd
in
fe
ct
io
n
0.
10
0*
**
0.
10
1*
**
1.
39
8*
**
1.
38
8*
**
0
0
0.
28
5*
**
0.
30
0*
**
0.
24
1*
*
0.
26
1*
**
In
te
rc
ep
t
9.
03
6*
**
8.
92
5*
**
8.
91
9*
**
8.
91
2*
**
8.
85
3*
**
8.
82
5*
**
9.
36
4*
**
8.
40
4*
**
8.
45
6*
**
9.
11
6*
**
8.
68
0*
**
8.
73
8*
**
11
.9
80
**
*
11
.5
99
**
*
11
.6
85
**
*
A
dj
us
te
d
R
²
0.
49
0.
49
0.
51
0.
23
0.
29
0.
42
0.
33
0.
50
0.
55
0.
55
0.
67
0.
70
0.
23
0.
34
0.
36
*p
<
0.
05
;
**
p
<
0.
01
;
**
*p
<
0.
00
1.
VARIATION IN COST AND LENGTH OF STAY AMONG CABG PATIENTS IN EUROPE 83
Copyright © 2012 John Wiley & Sons, Ltd. Health Econ. 21(Suppl. 2): 77–88 (2012)
DOI: 10.1002/hec
T
ab
le
II
I.
R
es
ul
ts
fr
om
th
e
pa
tie
nt
-l
ev
el
re
gr
es
si
on
s
fo
r
C
A
B
G
:
le
ng
th
of
st
ay
an
al
ys
es
(P
ar
t
II
)
D
ep
en
de
nt
va
ri
ab
le
:
le
ng
th
of
st
ay
A
us
tr
ia
F
ra
nc
e
Ir
el
an
d
P
ol
an
d
S
pa
in
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
D
R
G
1
1.
04
2
0.
84
7*
**
0.
87
4*
**
0.
95
8*
**
0.
65
4*
**
0.
93
6
0.
89
7*
**
0.
97
6*
re
f
re
f
D
R
G
2
re
f
re
f
1.
20
8*
**
1.
09
1*
**
0.
95
5
1.
12
5
re
f
re
f
1.
25
7*
*
1.
24
1
D
R
G
3
1.
12
1*
**
0.
90
4
re
f
re
f
1.
20
1*
*
1.
37
6*
**
1.
85
7*
**
1.
18
5*
**
D
R
G
4
1.
19
9*
0.
84
7*
0.
92
7*
**
0.
98
4
re
f
re
f
1.
76
4*
**
1.
27
9
D
R
G
5
1.
97
2*
**
1.
11
3*
1.
23
3*
**
1.
11
4*
**
1.
15
8*
0.
97
1
1.
83
2*
**
1.
17
7*
**
D
R
G
6
1.
20
0*
**
1.
06
3
1.
78
8*
**
1.
34
7*
**
2.
27
7*
**
1.
41
5
D
R
G
7
1.
39
6*
**
1.
13
2*
**
2.
55
2*
**
1.
69
7*
*
2.
21
5*
**
1.
52
5*
**
D
R
G
8
1.
11
7*
**
1.
07
4*
**
2.
64
6*
**
1.
81
1*
**
3.
93
6*
**
2.
53
8*
**
D
R
G
9
1.
53
4*
**
1.
17
4*
**
D
R
G
10
1.
76
8*
**
1.
21
3*
**
D
R
G
11
1.
43
1*
**
1.
20
8*
**
D
R
G
12
1.
99
7*
**
1.
27
3*
**
D
R
G
13
1.
87
2*
**
1.
44
4*
**
D
R
G
14
2.
18
2*
**
1.
58
2*
**
D
R
G
15
2.
39
0*
**
1.
43
6*
**
O
th
er
D
R
G
s
1.
23
5*
0.
78
2*
**
2.
33
0*
**
1.
40
4*
**
1.
99
9*
*
1.
3
1.
56
2*
**
1.
25
8*
**
1.
93
4*
**
1.
18
7
A
ge
:
1–
60
0.
98
0.
98
0.
98
1*
0.
98
0*
0.
91
2
0.
90
5*
0.
97
7*
0.
97
8*
0.
94
2
0.
93
5
A
ge
:6
0–
65
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
re
f
A
ge
:6
6–
70
1.
02
1.
01
7
1.
01
1
1.
01
1.
06
4
1.
06
7
1.
03
0*
1.
02
7*
0.
98
9
0.
98
1
A
ge
:7
1–
75
1.
06
8*
*
1.
07
4*
**
1.
01
9*
1.
01
8
1.
02
1
1.
03
1.
06
4*
**
1.
05
2*
**
1.
04
8
1.
06
6
A
ge
:
76
+
1.
13
3*
**
1.
12
6*
**
1.
06
2*
**
1.
05
4*
**
1.
07
3
1.
09
8
1.
13
1*
**
1.
11
7*
**
1.
11
4*
1.
13
4*
*
(C
on
tin
ue
s)
J. GAUGHAN ET AL.84
Copyright © 2012 John Wiley & Sons, Ltd. Health Econ. 21(Suppl. 2): 77–88 (2012)
DOI: 10.1002/hec
T
ab
le
II
I.
(C
on
tin
ue
d)
D
ep
en
de
nt
va
ri
ab
le
:
le
ng
th
of
st
ay
A
us
tr
ia
F
ra
nc
e
Ir
el
an
d
P
ol
an
d
S
pa
in
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
D
M
P
M
F
M
al
e
0.
93
8*
**
0.
93
4*
**
0.
97
0*
**
0.
96
6*
**
0.
94
7
0.
94
7
0.
99
3
0.
99
4
1.
04
3
1.
03
3
D
ia
gn
os
es
1.
02
6*
**
1.
02
5*
**
1.
02
6*
**
1.
01
9*
**
1.
04
3*
**
1.
03
9*
**
1.
03
0*
**
1.
02
9*
**
1.
04
8*
**
1.
03
7*
**
P
ro
ce
du
re
s
1.
13
2*
**
1.
13
4*
**
1.
04
9*
**
1.
04
1*
**
1.
06
8*
**
1.
04
1*
**
1.
04
7*
**
1.
04
6*
**
1.
13
2*
**
1.
08
4*
**
T
ra
ns
fe
r
in
0.
95
4*
0.
95
8*
1.
03
0*
**
1.
02
5*
**
0.
90
9
0.
93
6
1.
04
8
1.
04
6
T
ra
ns
fe
r
ou
t
0.
93
1*
**
0.
92
7*
**
0.
93
6*
**
0.
93
8*
**
1.
03
3
1.
05
3
0.
92
9*
**
0.
93
0*
**
0.
88
6*
0.
83
0*
**
E
m
er
ge
nc
y
1.
01
7
1.
01
3
1.
13
8*
**
1.
11
4*
**
1.
14
8*
*
1.
10
4*
1.
06
4*
**
1.
06
3*
**
1.
61
0*
**
1.
56
9*
**
D
ec
ea
se
d
0.
58
1*
**
0.
59
2*
**
0.
55
8*
**
0.
55
4*
**
0.
71
2*
*
0.
62
5*
**
0.
77
7*
**
0.
78
2*
**
0.
78
6*
0.
70
5*
**
C
h_
in
de
x
=
1
1.
01
5
1.
01
7
1.
00
3
1.
00
2
1.
11
4*
*
1.
11
0*
*
1.
00
3
0.
99
6
1.
05
5
1.
03
2
C
h_
in
de
x
=
2
1.
02
3
1.
01
8
1.
01
1
1.
01
8*
1.
20
4*
*
1.
17
1*
*
1.
03
7*
1.
03
1
1.
09
2*
1.
12
8*
*
U
ns
ta
bl
e
an
gi
na
0.
94
6*
0.
94
2*
0.
99
7
0.
99
3
1.
09
4*
1.
05
1.
00
9
1.
00
8
1.
06
1
1.
08
8*
A
tr
ia
l
ﬁ
br
ill
at
io
n
1.
03
1.
03
1
1.
02
5*
**
1.
02
3*
**
0.
99
2
1.
01
3
1.
02
7
1.
02
1
0.
98
9
0.
99
8
A
M
I
0.
93
2*
**
0.
93
2*
**
0.
99
6
0.
99
7
1.
08
7
1.
03
3
0.
94
0*
0.
92
8*
*
1.
01
4
1.
01
A
R
F
1.
20
0*
*
1.
18
4*
1.
05
9*
**
0.
99
1.
05
2
1.
03
3
1.
09
8
1.
10
2
1.
19
3*
*
1.
13
5*
M
ul
tip
le
C
A
B
G
s
0.
93
5
0.
95
6
0.
95
4
0.
95
5
N
A
N
A
N
A
N
A
0.
87
5*
*
0.
91
1*
P
T
C
A
0.
90
8
0.
90
1
0.
98
8
0.
95
3*
1.
17
7
1.
00
4
N
A
N
A
1.
01
6
1.
13
4
M
ul
tiv
es
se
l
C
A
B
G
0.
99
0.
91
0*
1.
02
2*
*
1.
02
6*
**
0.
98
7
1.
01
5
0.
99
7
0.
99
8
1.
14
6*
1.
14
8*
V
al
ve
su
rg
er
y
1.
01
9
1.
04
1
0.
97
4*
*
0.
94
7*
*
1.
15
0*
1.
06
7
1.
23
0*
**
1.
23
2*
**
1.
01
6
0.
87
4
A
dv
er
se
ev
en
t
0.
98
1
0.
95
7
1.
09
7*
**
1.
00
2
1.
05
9
1.
05
3
0.
75
1*
*
0.
74
6*
*
1.
22
5*
1.
21
3*
U
T
I
1.
12
4
1.
09
1.
03
3
1.
03
0.
97
5
1.
02
9
1
1
1.
21
8*
1.
25
8*
W
ou
nd
in
fe
ct
io
n
1.
63
3*
**
1.
61
1*
**
1.
31
0*
**
1.
17
8*
**
1.
34
9*
**
1.
38
2*
**
1
1
1.
71
2*
**
1.
73
3*
**
In
te
rc
ep
t
14
.9
92
**
*
8.
72
0*
**
9.
56
5*
**
11
.6
05
**
*
5.
68
3*
**
6.
27
7*
**
14
.6
53
**
*
5.
35
8*
**
6.
43
0*
**
10
.7
56
**
*
7.
24
6*
**
7.
41
4*
**
11
.4
43
**
*
4.
45
7*
**
5.
21
1*
**
D
is
pe
rs
io
n
0.
15
0*
**
0.
07
5*
**
0.
07
3*
**
0.
08
0*
**
0.
04
8*
**
0.
04
2*
**
0.
18
7*
**
0.
14
0*
**
0.
12
1*
**
0.
07
9*
**
0.
06
2*
**
0.
06
2*
**
0.
22
4*
**
0.
14
6*
**
0.
12
3*
**
A
dj
us
te
d
de
vi
an
ce
R
²
0.
14
0.
46
0.
47
0.
38
0.
54
0.
57
0.
39
0.
50
0.
56
0.
26
0.
35
0.
35
0.
37
0.
55
0.
60
*p
<
0.
05
;
**
p
<
0.
01
;
**
*p
<
0.
00
1.
VARIATION IN COST AND LENGTH OF STAY AMONG CABG PATIENTS IN EUROPE 85
Copyright © 2012 John Wiley & Sons, Ltd. Health Econ. 21(Suppl. 2): 77–88 (2012)
DOI: 10.1002/hec
In Estonia, Finland, Ireland and Spain, both MD and MP perform less well than MF, although in all four
countries, the explanatory power of MP is above that of MD. This implies that there is scope to reﬁne these
DRG systems to take other patient-level characteristics into account.
In Austria, France, Poland, Germany and Sweden, the explanatory power of MP and MF is similar and
considerably higher than that of MD. This raises questions about the adequacy of these DRG systems in explaining
variation in resource use among CABG patients. However, as wide variation in the number of DRGs used in these
systems demonstrates, reﬁnement might not necessarily entail expanding the number of DRGs.
3.2.2. Stage 2. As CABG is a specialised procedure, provision in most countries is concentrated into a subset of
hospitals. Therefore, in all countries, the number of hospitals was not sufﬁcient to undertake the second-stage
analyses. Figure 1 presents the unexplained variation in costs or LoS across these hospitals, after adjusting for
patient-level characteristics and DRGs (MF). Each hospital is represented by a vertical line (the 95% conﬁdence
interval) around a dot (the average cost or LoS of its CABG patients). The dashed horizontal line shows the
average cost or LoS for CABG cases in the national sample. Hospitals are ordered by ascending value.
The graphs demonstrate that all countries, with the exception of Estonia and Finland, have at least one
hospital with costs or LoS signiﬁcantly above and below the national sample average.
For hospitals on the right-hand side of the graphs, their position may partly reﬂect ‘inefﬁciency’, although
there may be legitimate reasons for the observed heterogeneity such as hospital or patient-level factors that
are omitted from our models (Dormont and Milcent, 2005).
4. DISCUSSION
This study examines the costs or LoS of 66 587 CABG patients treated in 146 hospitals in 10 European countries
to assess the predictive ability of each country’s DRG system. We have drawn upon routinely collected patient-
level data and, for most countries, included the full population of CABG patients treated during 2008. Three
regression models are used, in which resource use is explained by the DRGs to which patients are allocated
(MD), a set of patient and treatment-related characteristics constructed from routine data (MP) and a model that
includes both sets of variables (MF). As MD and MP are nested within MF, we are able to compare the relative
performance of these models, with these comparisons conducted separately for each country.
We ﬁnd substantial variation in the costs and LoS of patients undergoing CABG treatment. The results
are broadly similar for the cost and LoS analyses, although our explanatory variables are more frequently
statistically signiﬁcant in explaining patients’ LoS. The variables that most consistently explain variation are
the total number of diagnoses and procedures. No clear effects are evident for our CABG-speciﬁc diagnostic
and procedure variables. Wound infections signiﬁcantly increase LoS and costs in most countries, whereas
other types of adverse events have little impact.
The descriptive statistics show wide variation across countries in the diagnostic and treatment characteristics
of patients undergoing CABG, although demographic characteristics are similar. This variation is probably
partly because of differences in clinical or coding practice across counties. Cross-country comparisons must
therefore be made with caution, particularly when interpreting variables that rely on secondary diagnoses
(Drösler et al., 2009). Whatever its cause, in the face of such variation, it is not surprising that the DRGs that
countries use to classify CABG patients are structured so differently. The question arises as to which DRG
systems are best able to explain variations in observed resource use among patients.
For Austria, France, Poland, Germany and Sweden, MP is considerably more successful at explaining
variation in resource use than MD. This is despite France and Germany having the greatest number of DRGs
and using distinct means of subdividing categories (e.g. age, length of stay and death). In contrast, Austria
and Poland use the fewest DRGs to describe bypass procedures, not even using catheterisation as a classifying
distinction. For Estonia, Finland, Ireland and Spain, although MP explains more variation than MD, it has lower
explanatory power than MF that combines both sets of variables.
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All nine of these counties might beneﬁt from revising their DRG systems to incorporate some of the
information that we use to deﬁne our set of patient-level characteristics, particularly where the difference in
explanatory power between MP and MD is large. This does not necessarily mean increasing the number of
DRGs, bearing in mind the original objective that they should be kept to a manageable number (Fetter,
1991) and that we have not found a strong link between number of DRGs and explanatory power.
In England, the three models have similar explanatory power, implying there is little scope for reﬁning the
DRG system using the variables that we have examined. The English structure is unusual because it identiﬁes
ﬁrst and subsequent CABG procedures and has a separate DRG for CABG patients suffering from congenital
heart disease. However, MP does not provide an exhaustive description of patient variation, as it is inherently
limited by the availability of data in administrative datasets. The DRG systems in Estonia, Finland, Ireland and
Spain explain variations in resource use additional to that provided by our patient-level characteristics. If the
key features of these DRG grouping systems, such as the inclusion of particular procedures, could be identiﬁed,
this would offer insights to other countries seeking to reﬁne their DRGs.
Our analysis of CABG patients across Europe identiﬁes a series of factors, over and above the DRG to
which patients are allocated, that help explain variation in costs or LoS. These factors can be constructed from
routine data and might be used in the reﬁnement of DRGs themselves, although further research would need to
establish this, probably requiring application of traditional Classiﬁcation and Regression Tree methods to
deﬁne resource homogenous groupings.
Figure 1. CABG: variation in log of cost (N = 4) or length of stay (N= 5) between and within countries. Note: In Finland and Estonia, the
sample contains only one or two hospitals, so hospital effects have not been estimated.
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We also identify hospitals in each country whose patients have signiﬁcantly lower/higher resource use than
the national average, after accounting for the characteristics of the patients they treat. These hospitals stand to
gain/lose ﬁnancially if they are paid according to the DRGs to which their patients are allocated. The organisa-
tional features driving these differences in resource use might be established by site visits to hospitals at either
end of the distribution.
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